Scopus BioPharma Inc , a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases.
infoScopus BioPharma is a micro cap stock with a total market cap of 1.57M.
infoThey trade on the NASDAQ and had their IPO 2 years and 8 months ago.
infoScopus BioPharma currently employs 13 people.
infoAs of Wednesday, Aug 23 2023, Scopus BioPharma’s share price is $0.03725.
News Relating to Scopus BioPharma
GlobeNewsWire
Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — to Present at the 3rd Annual STING & TLR-Targeting Therapies Summit
Tuesday Mar 22 2022 at 20:30
Alan Horsager, Ph.D., President and Chief Executive Officer of Duet, to Present on TLR9 Activation and STAT3 Inhibition: A Bifunctional Approach to Immuno-Oncology
GlobeNewsWire
Scopus BioPharma Announces Adjournment of Annual Meeting of Stockholders
Friday Oct 08 2021 at 17:30
NEW YORK, Oct. 08, 2021 (GLOBE NEWSWIRE) — Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced that, on October 8, 2021, its 2021 Annual Meeting of Stockholders (the “Annual Meeting”) was adjourned to 1:00 p.m., Eastern time, on Friday, November 5, 2021, without any business being conducted, pursuant to a Stipulation and Court Order approved by the Delaware Court of Chancery between Scopus and Morris C. Laster, M.D. in connection with Dr. Laster’s pending claims against Scopus in the Delaware Court of Chancery. Notwithstanding the Stipulation and Court Order requiring Dr. Laster to cause all shares of Scopus common stock held by him to be present in person or by proxy at the Annual Meeting and any adjournments thereof exclusively for the purposes of establishing a quorum at the meeting, Dr. Laster failed to satisfy this requirement by both not attending the Annual Meeting in person and not making his shares present by proxy.
GlobeNewsWire
Scopus BioPharma to Present at the LD Micro Main Event
Tuesday Oct 05 2021 at 08:45
Scopus to present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology
GlobeNewsWire
Scopus BioPharma Retaining Counsel to Investigate Unusual Market Activity
Friday Oct 01 2021 at 16:30
NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) — Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company, announced today that it is retaining Boies Schiller Flexner LLP to conduct a market manipulation investigation.
GlobeNewsWire
Scopus BioPharma to Present at MicroCap Rodeo’s Fall Harvest Best Ideas Conference
Friday Oct 01 2021 at 07:00
Scopus to present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology
GlobeNewsWire
Scopus BioPharma’s Subsidiary — Duet Therapeutics — Announces Release of Preclinical Data Being Presented at 17th Annual Meeting of the Oligonucleotide Therapeutics Society
Wednesday Sep 29 2021 at 08:30
Data from two different studies benchmark Duet’s proprietary bifunctional oligonucleotides against immune checkpoint inhibitors (“Checkpoint Inhibitors”) in lymphoma and prostate tumor models in mice
GlobeNewsWire
Scopus BioPharma’s Subsidiary Duet Therapeutics Set to Release Scientific Data During the 17th Annual Meeting of the Oligonucleotide Therapeutics Society
Tuesday Sep 28 2021 at 09:15
Duet releases video depicting mechanism of action for its proprietary CpG-STAT3 inhibitors to coincide with Duet presentations at OTS Meeting Duet releases video depicting mechanism of action for its proprietary CpG-STAT3 inhibitors to coincide with Duet presentations at OTS Meeting
GlobeNewsWire
Scopus BioPharma’s Subsidiary — Duet Therapeutics — Set to Release Scientific Data During the 17th Annual Meeting of the Oligonucleotide Therapeutics Society
Tuesday Sep 28 2021 at 06:30
Duet releases video depicting mechanism of action for its proprietary CpG-STAT3 inhibitors to coincide with Duet presentations at OTS Meeting Duet releases video depicting mechanism of action for its proprietary CpG-STAT3 inhibitors to coincide with Duet presentations at OTS Meeting
GlobeNewsWire
Scopus BioPharma to Adjourn 2021 Annual Meeting of Stockholders
Tuesday Sep 28 2021 at 06:00
NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) — Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, announced today that, pursuant to a stipulation with Morris C. Laster, M.D. in connection with pending claims brought by Dr. Laster in the Delaware Court of Chancery, the company intends to convene, and then immediately adjourn, the company’s scheduled October 8, 2021 Annual Meeting of Stockholders (the “Annual Meeting”) such that the Annual Meeting will be held and the vote on the items of business to be considered at the Annual Meeting will be taken no earlier than 14 days after a decision on the merits or a final settlement between the parties. The company and Dr. Laster intend to conduct discussions in an effort to seek to resolve the disputes between the parties and have also agreed to an expedited timeline for resolving the Delaware court action.
GlobeNewsWire
Scopus BioPharma’s Subsidiary — Duet Therapeutics — to Present at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society
Wednesday Sep 22 2021 at 08:30
Alan Horsager, Ph.D., President and Chief Executive Officer of Duet Therapeutics, will present on CpG-STAT3 RNA Silencing and Antisense inhibitors
GlobeNewsWire
China National Intellectual Property Administration Grants New Patent Covering DUET-02, One of Three Key CpG-STAT3 Inhibitors Comprising the Duet Platform
Tuesday Sep 21 2021 at 09:00
New patent covers compound and composition and methods of use for CpG-STAT3 Antisense inhibitor (CpG-STAT3ASO)
PRNewsWire
Dr. Morris C. Laster Files Preliminary Proxy Statement Nominating Two Highly-Qualified Individuals For Election To Board At Scopus BioPharma Inc.’s 2021 Annual Meeting
Monday Sep 20 2021 at 09:05
JERUSALEM, Sept. 20, 2021 /PRNewswire/ — Dr. Morris C.
GlobeNewsWire
Scopus BioPharma’s Subsidiary — Duet Therapeutics — Announces Appointment of Marcin Kortylewski, Ph.D. as Senior Scientific Advisor
Tuesday Sep 07 2021 at 09:15
Dr. Kortylewski is the Leading Authority on Bi-Functional Oligonucleotide Cancer Therapeutics and a Professor in the Department of Immuno-Oncology at the Beckman Research Institute at City of Hope National Medical Center
GlobeNewsWire
Scopus BioPharma’s Subsidiary — Duet Therapeutics — to Present at the 14th Annual RNA Consortium Meeting
Friday Sep 03 2021 at 09:25
Alan Horsager, Ph.D., President and Chief Executive Officer of Duet, to Present on Clinical Development of CpG-STAT3 Inhibitors Alan Horsager, Ph.D., President and Chief Executive Officer of Duet, to Present on Clinical Development of CpG-STAT3 Inhibitors
GlobeNewsWire
Scopus BioPharma Launches Duet Therapeutics
Thursday Sep 02 2021 at 09:15
Duet Therapeutics Integrates Immunotherapy Assets of Scopus and Olimmune, Acquired by Scopus in June 2021
PennyStocks
5 Best Penny Stocks To Buy Right Now According To Insiders
Wednesday Aug 25 2021 at 10:53
5 Penny Stocks Insiders Are Buying Right Now The post 5 Best Penny Stocks To Buy Right Now According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
GlobeNewsWire
Scopus BioPharma Announces New Management Appointment Following Acquisition of Leading Immunotherapy Company
Monday Jul 12 2021 at 08:30
NEW YORK, July 12, 2021 (GLOBE NEWSWIRE) — Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical needs, today announced a new management appointment following its acquisition of Olimmune Inc., a leading immunotherapy company. Alan Horsager, Ph.D., President and Chief Executive of Olimmune, was appointed President of Scopus with responsibility for overseeing the development of the Company’s rapidly expanding immuno-oncology pipeline.
GlobeNewsWire
Scopus BioPharma Announces New Date for 2021 Annual Meeting of Stockholders
Monday May 31 2021 at 20:30
NEW YORK, May 31, 2021 (GLOBE NEWSWIRE) — Scopus BioPharma Inc. (Nasdaq: “SCPS”) today announced that the board of directors has rescheduled the company’s 2021 Annual Meeting of Stockholders (“2021 Annual Meeting”), which will be held on October 8, 2021.
GlobeNewsWire
Scopus BioPharma to Reschedule 2021 Annual Meeting of Shareholders
Wednesday May 26 2021 at 19:30
NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) — Scopus BioPharma Inc. (Nasdaq: “SCPS”) today announced it will be rescheduling the company’s 2021 Annual Meeting of Shareholders (the “2021 Annual Meeting”), which was previously scheduled for July 16, 2021. Once determined by the Scopus Board of Directors, the company will announce the new date, time and location of the 2021 Annual Meeting.
Pulse2
SCPS Stock Price: 71.98% Increase Explanation
Tuesday May 25 2021 at 08:40
The stock price of Scopus BioPharma Inc. (NASDAQ: SCPS) increased by 71.98% yesterday. This is why it happened.
Benzinga
Why Scopus BioPharma’s Stock Is Surging Today
Monday May 24 2021 at 14:45
Scopus BioPharma (NASDAQ:SCPS) shares are trading higher after the company announced the FDA has approved its IND application for CpG-STAT3siRNA, the company’s distinctive immuno-oncology RNA therapy for the treatment of multiple cancers. Scopus BioPharma’s stock has been rising Monday, up 102.07% to a price of $11.6.
Benzinga
Why Scopus, NGM Biopharma and Taiwan Liposome Are Moving Today
Monday May 24 2021 at 12:53
Scopus BioPharma Inc. (NASDAQ: SCPS), NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) and Taiwan Liposome Company, Ltd. (NASDAQ: TLC) are among the biggest biopharma movers Monday.
Benzinga
Why Scopus BioPharma Stock More Than Double Today?
Monday May 24 2021 at 12:53
The FDA has signed off investigational new drug application of Scopus BioPharma Inc’s (NASDAQ: SCPS) for CpG-STAT3siRNA, the company’s distinctive immuno-oncology RNA therapy for the treatment of multiple cancers. A Phase 1 clinical trial for B-cell non-Hodgkin lymphoma will be initiated at the City of Hope.
Invezz
Here’s why Scopus BioPharma gained 200% on Monday
Monday May 24 2021 at 12:25
Scopus BioPharma Inc. (NASDAQ: SCPS) said the U.S. Food and Drug Administration FDA approved its IND (investigational new drug) application on Monday for CpG-STAT3siRNA – its distinctive immuno-oncology RNA therapy that targets multiple types of cancers. Impact on the share price Following the announcement, Scopus BioPharma jumped roughly 200% in the stock market on Monday […] The post Here’s why Scopus BioPharma gained 200% on Monday appeared first on Invezz.
Pulse2
SCPS Stock Price: Over 200% Increase Explanation
Monday May 24 2021 at 10:42
The stock price of Scopus BioPharma Inc. (SCPS) increased by over 200% during intraday trading this morning. This is why it happened.
GlobeNewsWire
Scopus BioPharma Announces FDA Approval of IND Application for Lead Drug Candidate
Monday May 24 2021 at 09:30
CpG-STAT3siRNA is a Distinctive RNA Therapy and Immunotherapy Developed at City of Hope
PRNewsWire
Scopus BioPharma Announces Closing of Underwriters’ Over-Allotment Option in Full
Wednesday Feb 10 2021 at 20:05
NEW YORK, Feb. 10, 2021 /PRNewswire/ — Scopus BioPharma Inc. (Nasdaq: SCPS) today announced the closing of the underwriters’ over-allotment option in full, bringing total follow-on public offering proceeds to $10.35 million. Scopus is a biopharmaceutical company developing…
PRNewsWire
Underwriters Exercise Over-Allotment Option in Full, Brings Total Follow-On Public Offering Proceeds to $10.35 Million
Monday Feb 08 2021 at 19:00
NEW YORK, Feb. 8, 2021 /PRNewswire/ — Scopus BioPharma Inc. (Nasdaq: SCPS) today announced that the underwriters of the company’s follow-on public offering exercised their over-allotment option in full, bringing total proceeds to $10.35 million. The exercise of the over-allotment option…
PRNewsWire
Scopus BioPharma Announces Closing of $9 Million Follow-On Public Offering
Friday Jan 29 2021 at 20:00
NEW YORK, Jan. 29, 2021 /PRNewswire/ — Scopus BioPharma Inc. (Nasdaq: “SCPS”) today announced the closing of a $9 million follow-on public offering. The offering consisted of 1,000,000 shares of common stock at a public offering price of $9.00 per share. The company has granted the…
PRNewsWire
Scopus BioPharma Announces Completion of Clinical Lot Manufacture
Tuesday Jan 19 2021 at 07:00
NEW YORK, Jan. 19, 2021 /PRNewswire/ — Scopus BioPharma Inc. (Nasdaq: SCPS) today announced the completion of clinical lot manufacturing fulfilling the requirements for the planned Phase 1 clinical trial for non-Hodgkin’s lymphoma. This is a key milestone to enable finalization of the…
Scopus BioPharma Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Scopus BioPharma’s Altman Z-score is -250.79 which is in the distress zone. This indicates a higher risk of financial distress and potential bankruptcy for the company. It can serve as a warning sign of significant financial challenges, requiring careful consideration by potential investors.
Derived from SEC.GOV filing dataopen_in_new
Scopus BioPharma Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, there has been no insider trading in Scopus BioPharma.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Scopus BioPharma’s Income Quality of 0.35 is lower than its Industry Group of 0.69 (-49.3% lower)
Scopus BioPharma’s Income Quality of 0.35 is lower than its Major Industry Group of 0.71 (-50.7% lower)
Scopus BioPharma’s Income Quality of 0.35 is lower than its Sector of 0.75 (-53.3% lower)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Scopus BioPharma’s Current Ratio of 0.05 is lower than its Industry Group of 4.76 (-98.9% lower)
Scopus BioPharma’s Current Ratio of 0.05 is lower than its Major Industry Group of 4.32 (-98.8% lower)
Scopus BioPharma’s Current Ratio of 0.05 is lower than its Sector of 2.6 (-98.1% lower)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-0.18 & -1.27)
Cannot compare a negative PE Ratio (-0.18 & -1.1)
Cannot compare a negative PE Ratio (-0.18 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Cannot compare a negative PB Ratio (-0.15 & 1.34)
Cannot compare a negative PB Ratio (-0.15 & 1.4)
Cannot compare a negative PB Ratio (-0.15 & 1.62)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Scopus BioPharma’s ROE of 0.83 is greater than its Industry Group of -0.44 (288.6% greater)
Scopus BioPharma’s ROE of 0.83 is greater than its Major Industry Group of -0.38 (318.4% greater)
Scopus BioPharma’s ROE of 0.83 is greater than its Sector of -0.03 (2866.7% greater)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Scopus BioPharma’s ROCE of 249.7 is greater than its Industry Group of -0.42 (59552.4% greater)
Scopus BioPharma’s ROCE of 249.7 is greater than its Major Industry Group of -0.37 (67586.5% greater)
Scopus BioPharma’s ROCE of 249.7 is greater than its Sector of -0.04 (624350.0% greater)
Derived from SEC.GOV filing dataopen_in_new